Association between vedolizumab and risk of clostridium difficile infection in patients with ulcerative colitis: A systematic review and meta-analysis
Background: The medical treatment of ulcerative colitis (UC) includes the use of biological agents such as vedolizumab, a gut-selective alpha4beta7 (ɑ4β7) antagonist. The mechanism of action of vedolizumab involves interfering with leukocyte trafficking into the gut vasculature, which halts inflamma...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-11-01
|
| Series: | The Saudi Journal of Gastroenterology |
| Subjects: | |
| Online Access: | https://journals.lww.com/sjga/fulltext/2024/30060/association_between_vedolizumab_and_risk_of.2.aspx |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|